Chinese General Practice ›› 2023, Vol. 26 ›› Issue (35): 4446-4452.DOI: 10.12114/j.issn.1007-9572.2023.0195
Special Issue: 消化系统疾病最新文章合辑
• Article • Previous Articles Next Articles
Received:
2023-03-05
Revised:
2023-06-05
Published:
2023-12-15
Online:
2023-06-29
Contact:
DOU Weijia, LIU Zhenxiong
通讯作者:
窦维佳, 刘震雄
作者简介:
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2023.0195
组别 | 例数 | 性别〔例(%)〕 | 年龄( | 高血压〔例(%)〕 | 糖尿病〔例(%)〕 | 吸烟情况〔例(%)〕 | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
男 | 女 | 是 | 否 | 是 | 否 | 是 | 否 | |||||
对照组 | 151 | 103(68.2) | 48(31.8) | 50.0±11.1 | 128(84.8) | 23(15.2) | 127(84.1) | 24(15.9) | 112(74.2) | 39(25.8) | ||
再出血组 | 252 | 171(67.9) | 81(32.1) | 51.8±11.4 | 226(89.7) | 26(10.3) | 201(79.8) | 51(20.2) | 145(57.5) | 107(42.5) | ||
检验统计量值 | 0.005a | 1.502b | 2.135a | 1.176a | 11.306a | |||||||
P值 | 0.941 | 0.134 | 0.144 | 0.278 | 0.001 | |||||||
组别 | 肝硬化病因〔例(%)〕 | 腹腔积液〔例(%)〕 | 镜下红色征〔例(%)〕 | 门静脉血栓〔例(%)〕 | ||||||||
乙肝 | 丙肝 | 自身免疫 | 酒精 | 隐源 | 其他 | 无 | 有 | 无 | 有 | 无 | 有 | |
对照组 | 89(58.9) | 7(4.6) | 36(23.8) | 14(9.3) | 3(2.0) | 2(1.4) | 76(50.3) | 75(49.7) | 48(31.8) | 103(68.2) | 122(80.8) | 29(19.2) |
再出血组 | 150(59.5) | 22(8.7) | 53(21.0) | 17(6.8) | 5(2.0) | 5(2.0) | 61(24.2) | 191(75.8) | 33(13.1) | 219(86.9) | 130(51.6) | 122(48.4) |
检验统计量值 | 3.562a | 28.720a | 20.544a | 34.379a | ||||||||
P值 | 0.614 | <0.001 | <0.001 | <0.001 | ||||||||
组别 | 门静脉内径〔M(P25,P75),mm〕 | 血红蛋白〔M(P25,P75),g/L〕 | 血小板计数( | 白蛋白( | 白球比〔M(P25,P75)〕 | 总胆红素〔M(P25,P75),μmol/L〕 | 钠离子( | 凝血酶原时间( | D-二聚体〔M(P25,P75),μg/L〕 | 国际标准化比值〔M(P25,P75)〕 | ||
对照组 | 13(11,14) | 94(81,111) | 89.82±4.99 | 36.15±4.74 | 1.3(1.2,1.5) | 23.50(15.80,30.50) | 142.04±2.40 | 15.67±2.02 | 570(310,870) | 1.25(1.16,1.36) | ||
再出血组 | 15(13,16) | 83(70,94) | 78.81±3.90 | 32.98±5.81 | 1.3(1.2,1.5) | 25.30(17.32,36.32) | 137.06±3.54 | 16.40±2.91 | 2 000(940,4 130) | 1.34(1.19,1.55) | ||
检验统计量值 | 9.305c | 5.523c | 1.735b | 5.662b | 1.571c | -2.378c | 27.608b | 6.144b | 11.105c | -4.370c | ||
P值 | <0.001 | <0.001 | 0.083 | <0.001 | 0.080 | 0.017 | <0.001 | 0.140 | <0.001 | <0.001 |
Table 1 Univariate regression analysis of factors associated with rebleeding within 3 years after endoscopic treatment in cirrhotic patients with gastroesophageal variceal hemorrhage
组别 | 例数 | 性别〔例(%)〕 | 年龄( | 高血压〔例(%)〕 | 糖尿病〔例(%)〕 | 吸烟情况〔例(%)〕 | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
男 | 女 | 是 | 否 | 是 | 否 | 是 | 否 | |||||
对照组 | 151 | 103(68.2) | 48(31.8) | 50.0±11.1 | 128(84.8) | 23(15.2) | 127(84.1) | 24(15.9) | 112(74.2) | 39(25.8) | ||
再出血组 | 252 | 171(67.9) | 81(32.1) | 51.8±11.4 | 226(89.7) | 26(10.3) | 201(79.8) | 51(20.2) | 145(57.5) | 107(42.5) | ||
检验统计量值 | 0.005a | 1.502b | 2.135a | 1.176a | 11.306a | |||||||
P值 | 0.941 | 0.134 | 0.144 | 0.278 | 0.001 | |||||||
组别 | 肝硬化病因〔例(%)〕 | 腹腔积液〔例(%)〕 | 镜下红色征〔例(%)〕 | 门静脉血栓〔例(%)〕 | ||||||||
乙肝 | 丙肝 | 自身免疫 | 酒精 | 隐源 | 其他 | 无 | 有 | 无 | 有 | 无 | 有 | |
对照组 | 89(58.9) | 7(4.6) | 36(23.8) | 14(9.3) | 3(2.0) | 2(1.4) | 76(50.3) | 75(49.7) | 48(31.8) | 103(68.2) | 122(80.8) | 29(19.2) |
再出血组 | 150(59.5) | 22(8.7) | 53(21.0) | 17(6.8) | 5(2.0) | 5(2.0) | 61(24.2) | 191(75.8) | 33(13.1) | 219(86.9) | 130(51.6) | 122(48.4) |
检验统计量值 | 3.562a | 28.720a | 20.544a | 34.379a | ||||||||
P值 | 0.614 | <0.001 | <0.001 | <0.001 | ||||||||
组别 | 门静脉内径〔M(P25,P75),mm〕 | 血红蛋白〔M(P25,P75),g/L〕 | 血小板计数( | 白蛋白( | 白球比〔M(P25,P75)〕 | 总胆红素〔M(P25,P75),μmol/L〕 | 钠离子( | 凝血酶原时间( | D-二聚体〔M(P25,P75),μg/L〕 | 国际标准化比值〔M(P25,P75)〕 | ||
对照组 | 13(11,14) | 94(81,111) | 89.82±4.99 | 36.15±4.74 | 1.3(1.2,1.5) | 23.50(15.80,30.50) | 142.04±2.40 | 15.67±2.02 | 570(310,870) | 1.25(1.16,1.36) | ||
再出血组 | 15(13,16) | 83(70,94) | 78.81±3.90 | 32.98±5.81 | 1.3(1.2,1.5) | 25.30(17.32,36.32) | 137.06±3.54 | 16.40±2.91 | 2 000(940,4 130) | 1.34(1.19,1.55) | ||
检验统计量值 | 9.305c | 5.523c | 1.735b | 5.662b | 1.571c | -2.378c | 27.608b | 6.144b | 11.105c | -4.370c | ||
P值 | <0.001 | <0.001 | 0.083 | <0.001 | 0.080 | 0.017 | <0.001 | 0.140 | <0.001 | <0.001 |
变量 | B | SE | Waldχ2值 | P值 | OR(95%CI) |
---|---|---|---|---|---|
吸烟 | 0.916 | 0.361 | 6.447 | 0.011 | 2.499(1.232,5.066) |
门静脉血栓 | 0.611 | 0.364 | 2.810 | 0.094 | 1.842(0.902,3.763) |
门静脉内径 | 0.046 | 0.009 | 23.966 | <0.001 | 1.047(1.028,1.066) |
腹腔积液 | 0.314 | 0.363 | 0.748 | 0.387 | 1.369(0.672,2.789) |
血红蛋白 | -0.002 | 0.008 | 0.051 | 0.822 | 0.998(0.983,1.013) |
血清白蛋白 | 0.022 | 0.038 | 0.343 | 0.558 | 1.022(0.950,1.100) |
钠离子 | -0.432 | 0.074 | 34.400 | <0.001 | 0.649(0.562,0.750) |
国际标准化比值 | -0.977 | 0.870 | 1.314 | 0.252 | 0.369(0.067,2.029) |
镜下红色征 | 1.106 | 0.415 | 7.177 | 0.008 | 3.023(1.341,6.814) |
D-二聚体 | 0.001 | 0 | 30.382 | <0.001 | 1.001(1.001,1.001) |
总胆红素 | 0.010 | 0.012 | 0.679 | 0.410 | 1.010(0.986,1.034) |
血小板计数 | 0.001 | 0.003 | 0.096 | 0.756 | 1.001(0.995,1.007) |
白球比 | -0.565 | 0.496 | 1.301 | 0.254 | 0.568(0.215,1.501) |
Table 2 Multivariate Logistic regression analysis of risk factors associated with rebleeding within 3 years after endoscopic treatment in cirrhotic patients with gastroesophageal variceal hemorrhage
变量 | B | SE | Waldχ2值 | P值 | OR(95%CI) |
---|---|---|---|---|---|
吸烟 | 0.916 | 0.361 | 6.447 | 0.011 | 2.499(1.232,5.066) |
门静脉血栓 | 0.611 | 0.364 | 2.810 | 0.094 | 1.842(0.902,3.763) |
门静脉内径 | 0.046 | 0.009 | 23.966 | <0.001 | 1.047(1.028,1.066) |
腹腔积液 | 0.314 | 0.363 | 0.748 | 0.387 | 1.369(0.672,2.789) |
血红蛋白 | -0.002 | 0.008 | 0.051 | 0.822 | 0.998(0.983,1.013) |
血清白蛋白 | 0.022 | 0.038 | 0.343 | 0.558 | 1.022(0.950,1.100) |
钠离子 | -0.432 | 0.074 | 34.400 | <0.001 | 0.649(0.562,0.750) |
国际标准化比值 | -0.977 | 0.870 | 1.314 | 0.252 | 0.369(0.067,2.029) |
镜下红色征 | 1.106 | 0.415 | 7.177 | 0.008 | 3.023(1.341,6.814) |
D-二聚体 | 0.001 | 0 | 30.382 | <0.001 | 1.001(1.001,1.001) |
总胆红素 | 0.010 | 0.012 | 0.679 | 0.410 | 1.010(0.986,1.034) |
血小板计数 | 0.001 | 0.003 | 0.096 | 0.756 | 1.001(0.995,1.007) |
白球比 | -0.565 | 0.496 | 1.301 | 0.254 | 0.568(0.215,1.501) |
Figure 1 Nomogram risk prediction model of rebleeding within 3 years after endoscopic treatment in cirrhotic patients with gastroesophageal variceal hemorrhage
Figure 2 ROC curve of the nomogram risk prediction model of rebleeding within 3 years after endoscopic treatment in cirrhotic patients with gastroesophageal variceal hemorrhage
Figure 3 Calibration curve of the nomogram risk prediction model of rebleeding within 3 years after endoscopic treatment in cirrhotic patients with gastroesophageal variceal hemorrhage
[1] |
European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis[J]. J Hepatol,2018,69(2):406-460. DOI:10.1016/j.jhep.2018.03.024.
|
[2] |
|
[3] |
中华医学会肝病学分会,中华医学会消化病学分会,中华医学会内镜学分会. 肝硬化门静脉高压食管胃静脉曲张出血防治指南(2015)[J]. 中华胃肠内镜电子杂志,2015,2(4):1-21. DOI:10.3877/cma.j.issn.2095-7157.2015.04.001.
|
[4] |
杨连粤,白雪莉. 肝硬化门静脉高压症食管、胃底静脉曲张破裂出血诊治专家共识(2019版)[J]. 中国实用外科杂志,2019,39(12):1241-1247. DOI:10.19538/j.cjps.issn1005-2208.2019.12.01.
|
[5] |
|
[6] |
|
[7] |
|
[8] |
|
[9] |
|
[10] |
|
[11] |
刘朴卉,刘一品,徐宁,等. HBV-DNA定量、肝脏硬度值与乙肝肝硬化并食管胃静脉曲张出血内镜治疗后早期再出血的相关性研究[J]. 滨州医学院学报,2019,42(2):96-98. DOI:10.19739/j.cnki.issn1001-9510.2019.02.005.
|
[12] |
刘庆伟,王婧,刘静,等. 肝硬化食管静脉曲张首次套扎术后再出血危险因素分析[J]. 世界最新医学信息文摘,2019,19(59):33-34,36. DOI:10.19613/j.cnki.1671-3141.2019.59.013.
|
[13] |
皮奉武,李国庆. 内镜联合奥曲肽治疗肝硬化食管静脉曲张破裂出血患者后再出血的影响因素分析[J]. 现代诊断与治疗,2021,32(19):3092-3093.
|
[14] |
任丽梅,党彤,孟宪梅,等. 肝硬化食管静脉曲张出血内镜治疗后早期再出血的危险因素分析[J]. 中华胃肠内镜电子杂志,2019,6(2):57-61. DOI:10.3877/cma.j.issn.2095-7157.2019.02.002.
|
[15] |
李龙辉,王宇,高文广,等. 肝硬化食管胃静脉曲张破裂出血患者内镜治疗后再出血的影响因素分析[J]. 中华保健医学杂志,2022,24(5):399-401.
|
[16] |
马佳丽,何玲玲,李坪,等. 饮酒量对酒精性肝硬化食管胃静脉曲张患者肝功能及再出血的影响[J]. 临床肝胆病杂志,2019,35(11):2478-2482. DOI:10.3969/j.issn.1001-5256.2019.11.018.
|
[17] |
吴苑,陈明榆,黄梦芬,等. 紫色征对肝硬化静脉曲张破裂出血患者内镜治疗后再出血风险的预测作用[J]. 南方医科大学学报,2021,41(12):1822-1827. DOI:10.12122/j.issn.1673-4254.2021.12.10.
|
[18] |
赵睿,顾林,柯希权,等. 影响肝硬化食管胃底静脉曲张内镜治疗效果的多因素分析[J]. 蚌埠医学院学报,2022,47(8):1062-1065. DOI:10.13898/j.cnki.issn.1000-2200.2022.08.017.
|
[19] | |
[20] |
|
[21] |
|
[22] |
金苏云. TIPS、内镜预防肝硬化静脉曲张再出血疗效的多因素分析[D]. 济南:山东大学,2020.
|
[23] |
|
[24] |
舒梦妮,李树臣. 血清钠对肝硬化患者预后的影响[J]. 哈尔滨医科大学学报,2014,48(6):528-531.
|
[25] |
|
[26] |
|
[27] |
|
[28] |
|
[29] |
|
[30] |
崔璨璨,李丹丹,李长锋,等. 食管静脉曲张首次套扎术后早期再出血的危险因素分析[J]. 临床肝胆病杂志,2018,34(7):1445-1451. DOI:10.3969/j.issn.1001-5256.2018.07.017.
|
[31] |
|
[32] |
张雯,刘福全,张林鹏,等. 中国肝静脉压力梯度临床应用现状:一项基于CHESS-HVPG协作组的调研分析[J]. 中华肝脏病杂志,2022,32(6):637-643.
|
[33] | |
[34] |
|
[35] |
|
[36] |
陈斯阳,高青. 食管胃底静脉曲张内镜治疗术后早期再出血的危险因素探讨 [J]. 世界最新医学信息文摘(连续型电子期刊),2020,20(24):25-26. DOI:10.3969/j.issn.1671-3141.2020.24.010.
|
[37] |
郭雅丽,徐宝宏,刘贤,等. 食管静脉曲张内镜治疗术后早期再出血的危险因素分析[J]. 中华消化内镜杂志,2018,35(2):89-93. DOI:10.3760/cma.j.issn.1007-5232.2018.02.003.
|
[38] |
黄理,陈丽芬,蓝婧,等. 肝硬化食管静脉曲张内镜下治疗后早期再出血的危险因素研究[J]. 现代消化及介入诊疗,2019,24(9):1035-1038. DOI:10.3969/j.issn.1672-2159.2019.09.024.
|
[1] | XU Baichuan, WANG Yan, ZHANG Peng, LI Yiting, LIU Feilai, XIE Yang. Research and Analysis of Screening Tools for Chronic Obstructive Pulmonary Disease Comorbidity Lung Cancer [J]. Chinese General Practice, 2025, 28(30): 3847-3852. |
[2] | SHAO Xiaoying, SHAO Jie, ZHU Yan, SHAO Jinling, SHANG Ling, WU Zhenlian, ZHAO Yu, ZHANG Jiacai. Analysis of the Current Status of Iron Deficiency and Factors Affecting Iron Deficiency Anemia among Children Aged 6-36 Months in Guizhou Province [J]. Chinese General Practice, 2025, 28(27): 3368-3374. |
[3] | ZHOU Qian, WU Xiaomin, WANG Baohua, YAN Ruohan, YU Miao, WU Jing. Study on Nomogram Prediction Model for Risk of Gastric Cancer [J]. Chinese General Practice, 2025, 28(23): 2870-2877. |
[4] | GUO Shengteng, ZHANG Fenfen, WAN Di, YU Dongmei, WANG Qinghua. Risk Factors for Severe Acute Pancreatitis Complicated with Acute Lung Injury: a Meta-analysis [J]. Chinese General Practice, 2025, 28(20): 2546-2554. |
[5] | WANG Xiaoyu, FENG Zhenzhen, WANG Jun, GUO Xiaochuan, LI Jiansheng. Risk Factors for Acute Kidney Injury in Acute Respiratory Distress Syndrome: a Systematic Review [J]. Chinese General Practice, 2025, 28(12): 1527-1537. |
[6] | CHI Xun, LIU Sisi, CHEN Qiao, HU Yue, WANG Weixian. The Suitability of Four Nutritional Screening Tools for Nutritional Screening in Patients with Cirrhosis: a Network Meta-analysis [J]. Chinese General Practice, 2025, 28(11): 1395-1402. |
[7] | LIAO Xingyu, TIAN Siyu, CHEN Min. The Disease Burden, Risk Factors and Predictive Analysis of Early-onset Colorectal Cancer of Different Genders between China and the World from 1990 to 2021 [J]. Chinese General Practice, 2025, 28(08): 1004-1011. |
[8] | ZOU Songyan, ZHANG Riyi, LI Xiaodong, MU Yinyu. Analysis of Clinical Characteristics and Risk Factors of Systemic Sclerosis Combined with Sjögren's Syndrome [J]. Chinese General Practice, 2025, 28(06): 737-741. |
[9] | SHI Xiaotian, WANG Shan, YANG Huayu, YANG Yifan, LI Xu, DOU Guoze, MA Qing. A Predictive Nomogram for the Risk of Frailty/Pre-frailty on Inflammatory Biomarkers in the Elderly [J]. Chinese General Practice, 2025, 28(05): 587-593. |
[10] | KONG Linghong, XIE Xiaoxin, FU Yanhua, GAN Lin, YANG Xiaoyan, MA Shujing, LONG Hai. Pre-treatment and Acquired Antiretroviral Drug Resistance among People Living with HIV in Southwest China [J]. Chinese General Practice, 2025, 28(02): 242-249. |
[11] | LIU Mingbo, HE Xinye, YANG Xiaohong, WANG Zengwu. Interpretation of Report on Cardiovascular Health and Diseases in China 2023 [J]. Chinese General Practice, 2025, 28(01): 20-38. |
[12] | TAO Jintao, WU Shouling, ZHAO Xiaohong. Prevalence and Risk Factors of Atrioventricular Block in the Population: a Study Based on the Kailuan Cohort [J]. Chinese General Practice, 2024, 27(36): 4534-4539. |
[13] | GU Shanye, ZHOU Ziyi, CAI Yefeng. Study on Risk Prediction of Non-dementia Vascular Cognitive Impairment in Glycolipid Metabolic Diseases [J]. Chinese General Practice, 2024, 27(35): 4412-4416. |
[14] | ZHANG Bingqing, HU Xinyun, OUYANG Yuqin, XIANG Xinyue, TANG Wenjuan, FENG Wenhuan. Study on Nomogram Prediction Model for Risk Factors of Muscle Mass Loss in Non-obese Patients with Type 2 Diabetes [J]. Chinese General Practice, 2024, 27(33): 4139-4146. |
[15] | Diabetes and Microcirculation Professional Committee of Chinese Society of Microcirculation, Primary Endocrine and Metabolic Diseases Group of the Chinese Society of Endocrinology. Expert Consensus on Screening and Prevention of Diabetic Microvascular Disease for Primary Care (2024) [J]. Chinese General Practice, 2024, 27(32): 3969-3986. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||